Results 21 to 30 of about 5,263,232 (399)

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Molecular Cancer, 2022
The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhenjun Shi, Lin Hao, Xiao-xiao Han, Zhuoxun Wu, K. Pang, Yang Dong, Jia-Xin Qin, Guangrong Wang, Xuan Zhang, Tian Xia, Q. Liang, Yan Zhao, Rui Li, Shaoqi Zhang, Junhao Zhang, Jiangang Chen, Gong-cheng Wang, Zhe‐Sheng Chen, Conghui Han   +18 more
semanticscholar   +1 more source

The role of the HIF‐1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer

Cancer Communications, 2021
As a rate‐limiting enzyme of glycolysis, pyruvate kinase muscle isozyme M2 (PKM2) participates in tumor metabolism and growth. The regulatory network of PKM2 in cancer is complex and has not been fully studied in bladder cancer. The 5‐methylcytidine (m5C)
Jing-zi Wang, Wei Zhu, Jie Han, X. Yang, R. Zhou, Hongcheng Lu, Hao Yu, Wenbo Yuan, Pengchao Li, J. Tao, Q. Lu, Ji-Fu Wei, Haiwei Yang   +12 more
semanticscholar   +1 more source

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2020
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and ...
T. Flaig, Philippe E. Spiess, N. Agarwal, R. Bangs, S. Boorjian, M. Buyyounouski, Sam S. Chang, Tracy M. Downs, J. Efstathiou, T. Friedlander, R. Greenberg, K. Guru, T. Guzzo, H. Herr, J. Hoffman-Censits, C. Hoimes, B. Inman, M. Jimbo, A. Kader, S. Lele, J. Michalski, J. Montgomery, L. Nandagopal, Lance C. Pagliaro, S. Pal, A. Patterson, E. Plimack, K. Pohar, M. Preston, W. Sexton, A. Siefker-Radtke, J. Tward, J. Wright, Lisa A. Gurski, Alyse Johnson-Chilla   +34 more
semanticscholar   +1 more source

Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells

Cell Death and Disease, 2021
Ferroptosis is a form of regulated cell death that emerges to be relevant for therapy-resistant and dedifferentiating cancers. Although several lines of evidence suggest that ferroptosis is a type of autophagy-dependent cell death, the underlying ...
Yadong Sun, N. Berleth, Wenxian Wu, David Schlütermann, J. Deitersen, Fabian Stuhldreier, Lena Berning, Annabelle Friedrich, Seda Akgün, M. J. Mendiburo, S. Wesselborg, M. Conrad, C. Berndt, B. Stork   +13 more
semanticscholar   +1 more source

International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members

European Urology Open Science, 2023
Background: Grade of non–muscle-invasive bladder cancer (NMIBC) is an important prognostic factor for progression. Currently, two World Health Organization (WHO) classification systems (WHO1973, categories: grade 1–3, and WHO2004 categories: papillary ...
Irene J. Beijert, Liang Cheng, Fredrik Liedberg, Karin Plass, Sean R. Williamson, Paolo Gontero, Maria J. Ribal, Marko Babjuk, Peter C. Black, Ashish M. Kamat, Ferran Algaba, David M. Berman, Arndt Hartmann, Alexandra Masson-Lecomte, Morgan Rouprêt, Antonio Lopez-Beltran, Hemamali Samaratunga, Shahrokh F. Shariat, A. Hugh Mostafid, Murali Varma, Steven Shen, Maximilian Burger, Toyonori Tsuzuki, Joan Palou, Eva M. Compérat, Richard J. Sylvester, Theo H. van der Kwast, Bas W.G. van Rhijn, Michelle R. Downes   +28 more
doaj   +1 more source

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]

, 2019
Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph, Ghosh, Paramita M, He, Wei, Hum, Nicholas R, Loots, Gabriela G, Martin, Kelly A, Pan, Chong-Xian, Sebastian, Aimy, Siddiqui, Salma   +8 more
core   +2 more sources

Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management

Frontiers in Oncology, 2021
Precision medicine approaches that inform clinical management of individuals with cancer are progressively advancing. Patient-derived explants (PDEs) provide a patient-proximal ex vivo platform that can be used to assess sensitivity to standard of care ...
Abby R. Templeton, Abby R. Templeton, Abby R. Templeton, Abby R. Templeton, Penny L. Jeffery, Penny L. Jeffery, Penny L. Jeffery, Penny L. Jeffery, Patrick B. Thomas, Patrick B. Thomas, Patrick B. Thomas, Patrick B. Thomas, Mahasha P. J. Perera, Mahasha P. J. Perera, Mahasha P. J. Perera, Mahasha P. J. Perera, Mahasha P. J. Perera, Gary Ng, Gary Ng, Alivia R. Calabrese, Alivia R. Calabrese, Alivia R. Calabrese, Alivia R. Calabrese, Clarissa Nicholls, Clarissa Nicholls, Clarissa Nicholls, Nathan J. Mackenzie, Nathan J. Mackenzie, Nathan J. Mackenzie, Nathan J. Mackenzie, Jack Wood, Jack Wood, Jack Wood, Laura J. Bray, Laura J. Bray, Laura J. Bray, Ian Vela, Ian Vela, Ian Vela, Ian Vela, Ian Vela, Erik W. Thompson, Erik W. Thompson, Elizabeth D. Williams, Elizabeth D. Williams, Elizabeth D. Williams, Elizabeth D. Williams   +46 more
doaj   +1 more source

Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker. [PDF]

, 2018
Though bladder urothelial carcinoma is the most common form of bladder cancer, advances in its diagnosis and treatment have been modest in the past few decades.
Li, Wei Tse, Nguyen, Vincent, Ongkeko, Weg M, Wang-Rodriguez, Jessica, Zheng, Hao   +4 more
core   +2 more sources

Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m6A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer

Cancer Research, 2021
A newly characterized circRNA circ0008399 binds WTAP to modulate expression of target RNA through m6A modification and reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Wenjie Wei, Jiayin Sun, Hui Zhang, Xingyuan Xiao, Chao Huang, Liang Wang, H. Zhong, Yangkai Jiang, Xiaoping Zhang, Guosong Jiang   +9 more
semanticscholar   +1 more source

Autophagy and urothelial carcinoma of the bladder: A review. [PDF]

, 2016
The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the
Chandrasekar, Thenappan, Evans, Christopher P   +1 more
core   +2 more sources